FDA Sends Batch Of DSCSA Guidances To White House For Review

The White House is reviewing a batch of four draft and final guidances from FDA that lay out how drug makers can comply with certain requirements under the Drug Supply Chain Security Act, including how they can identify and notify FDA of illegitimate drug products, and how to include product identifiers with product packages. One draft guidance also addresses enhanced drug distribution security. FDA sent the guidances -- two draft and two final -- to the White House Office of...